BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 9712921)

  • 1. Cardiovascular safety of lubeluzole (Prosynap(R)) in patients with ischemic stroke.
    Hacke W; Lees KR; Timmerhuis T; Haan J; Hantson L; Hennerici M; Diener HC
    Cerebrovasc Dis; 1998; 8(5):247-54. PubMed ID: 9712921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety and tolerability of single intravenous doses of lubeluzole (Prosynap) in healthy volunteers.
    Hantson L; Tritsmans L; Crabbé R; Gheuens J; Van Rooy P
    Int J Clin Pharmacol Ther; 1997 Nov; 35(11):491-5. PubMed ID: 9401829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lubeluzole in acute ischemic stroke. A double-blind, placebo-controlled phase II trial. Lubeluzole International Study Group.
    Diener HC; Hacke W; Hennerici M; RĂ„dberg J; Hantson L; De Keyser J
    Stroke; 1996 Jan; 27(1):76-81. PubMed ID: 8553408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lubeluzole treatment of acute ischemic stroke. The US and Canadian Lubeluzole Ischemic Stroke Study Group.
    Grotta J
    Stroke; 1997 Dec; 28(12):2338-46. PubMed ID: 9412611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke. European and Australian Lubeluzole Ischaemic Stroke Study Group.
    Diener HC
    Cerebrovasc Dis; 1998; 8(3):172-81. PubMed ID: 9619701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lubeluzole in acute ischemic stroke treatment: A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo.
    Diener HC; Cortens M; Ford G; Grotta J; Hacke W; Kaste M; Koudstaal PJ; Wessel T
    Stroke; 2000 Nov; 31(11):2543-51. PubMed ID: 11062273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and pharmacokinetics of the neuroprotective drug lubeluzole in patients with ischemic stroke.
    De Keyser J; Van de Velde V; Schellens RL; Hantson L; Tritsmans L; Gheuens J; Van Peer A; Woestenborghs R; Franke CL; van Gorp J
    Clin Ther; 1997; 19(6):1340-51. PubMed ID: 9444444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of the dose proportionality of single intravenous doses (5, 10, and 15 mg) of lubeluzole in healthy volunteers.
    Herron J; Lee P; Pesco-Koplowitz L; Gajjar D; Soo YW; Woestenborghs R
    Clin Ther; 1998; 20(4):682-90. PubMed ID: 9737828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination Therapy Stroke Trial: recombinant tissue-type plasminogen activator with/without lubeluzole.
    Grotta J;
    Cerebrovasc Dis; 2001; 12(3):258-63. PubMed ID: 11641593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lubeluzole treatment of acute ischemic stroke.
    Lodder J
    Stroke; 1998 May; 29(5):1067. PubMed ID: 9596259
    [No Abstract]   [Full Text] [Related]  

  • 11. Lubeluzole for acute ischaemic stroke.
    Gandolfo C; Sandercock P; Conti M
    Cochrane Database Syst Rev; 2002; (1):CD001924. PubMed ID: 11869612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the antihypoxic and neuroprotective drug, lubeluzole, on repolarization phase of canine heart assessed by monophasic action potential recording.
    Sugiyama A; Ni C; Arita J; Eto K; Xue YX; Hashimoto K
    Toxicol Appl Pharmacol; 1996 Jul; 139(1):109-14. PubMed ID: 8685892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lubeluzole. JK 8792, R 87926, Prosynap.
    Drugs R D; 1999 Jan; 1(1):29-31. PubMed ID: 10565978
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetics of lubeluzole (Prosynap) after single intravenous doses in healthy subjects.
    Van de Velde V; Crabbe R; Van Peer A; Woestenborghs R; Van Osselaer N; Hantson L; Heykants J
    Int J Clin Pharmacol Ther; 1998 Sep; 36(9):490-3. PubMed ID: 9760010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
    Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
    Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT).
    Teal P; Davis S; Hacke W; Kaste M; Lyden PD; ; Fierus M;
    Stroke; 2009 Nov; 40(11):3518-25. PubMed ID: 19745176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial.
    Nelson HS; Gross NJ; Levine B; Kerwin EM; Rinehart M; Denis-Mize K;
    Clin Ther; 2007 Oct; 29(10):2167-78. PubMed ID: 18042473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-molecular-weight heparin for the treatment of acute ischemic stroke.
    Kay R; Wong KS; Yu YL; Chan YW; Tsoi TH; Ahuja AT; Chan FL; Fong KY; Law CB; Wong A
    N Engl J Med; 1995 Dec; 333(24):1588-93. PubMed ID: 7477193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of experimental focal ischemia in rats with lubeluzole.
    Aronowski J; Strong R; Grotta JC
    Neuropharmacology; 1996 Jun; 35(6):689-93. PubMed ID: 8887977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings.
    Noel GJ; Goodman DB; Chien S; Solanki B; Padmanabhan M; Natarajan J
    J Clin Pharmacol; 2004 May; 44(5):464-73. PubMed ID: 15102866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.